Lexaria Bioscience Advances 2021 Strategic Initiat
Post# of 338
(Total Views: 283)
Posted On: 12/20/2020 11:34:50 AM
Lexaria Bioscience Advances 2021 Strategic Initiatives
https://www.lexariabioscience.com/
There are an increasing number of alternatives to combustible tobacco experiencing dramatic growth in demand as consumers search for reduced risk method nicotine options, including the e-cig marke t, currently valued at $12.41 billion and projected to reach $68.48 billion by 2027; as well as the nicotine oral pouch market, currently valued at $2.37 billion and expected to reach $32.77 billion by 2026.(5) Products in the oral pouch category were the first nicotine products in the history of the Food and Drug Administration (the "FDA"
to be authorized through the Modified Risk Tobacco Product pathway approved for claims of a lower risk of mouth cancer, stoke, lung disease, heart disease, emphysema and chronic bronchitis than cigarettes.
Lexaria has been successful in developing relationships with two of the world's largest tobacco companies, Altria Ventures Inc and British American Tobacco. Lexaria has also engaged in business dialogue with other tobacco and nicotine companies located in various parts of the world. Lexaria's DehydraTECH is patent granted in the USA, the European Union and Australia for oral delivery of nicotine.
https://www.lexariabioscience.com/
There are an increasing number of alternatives to combustible tobacco experiencing dramatic growth in demand as consumers search for reduced risk method nicotine options, including the e-cig marke t, currently valued at $12.41 billion and projected to reach $68.48 billion by 2027; as well as the nicotine oral pouch market, currently valued at $2.37 billion and expected to reach $32.77 billion by 2026.(5) Products in the oral pouch category were the first nicotine products in the history of the Food and Drug Administration (the "FDA"
to be authorized through the Modified Risk Tobacco Product pathway approved for claims of a lower risk of mouth cancer, stoke, lung disease, heart disease, emphysema and chronic bronchitis than cigarettes. Lexaria has been successful in developing relationships with two of the world's largest tobacco companies, Altria Ventures Inc and British American Tobacco. Lexaria has also engaged in business dialogue with other tobacco and nicotine companies located in various parts of the world. Lexaria's DehydraTECH is patent granted in the USA, the European Union and Australia for oral delivery of nicotine.
(0)
(0)
Robert
Scroll down for more posts ▼